GeneLink BioSciences, Inc. REPORTS REVENUE FOR THIRD QUARTER 2002
November 14, 2002

MARGATE, NJ - (Business Wire) - November 14, 2002 - GeneLink BioSciences, Inc. (OTCBB:GNLK), a bioscience company and a leader of genetic assessments direct-to-consumer, announced today that the Company has reported revenue for the third quarter 2002. 

In August, 2002, GeneLink began to license its nutragenetic and dermagenetic profiles to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement and healthcare industries. Revenue generated from these sales are approximately $26,000. 

"This is a very important beginning for GeneLink", says John R. DePhillipo, Chairman and CEO of the Company. "We made significant progress in the third quarter in sharpening GeneLink's business focus, strengthening our licensee teams and setting the stage for continued growth and achievement of profitability. This initial revenue demonstrates the ability and success of GeneLink's proprietary genetic assessments to the personal care industry. It is our belief that this revenue will continue to grow significantly as more and more licensees sign up to use our genetic assessments to deliver customized cosmetics and nutritional products directly to the consumer." GeneLink's form 10-SQB for the quarter period ending September 30, 2002, can be viewed at www.sec.gov. 

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.